Combivent (ipratropium bromide and albuterol sulfate) is a combination of ipratropium bromide (as the monohydrate) and albuterol sulfate. These medications are used as rescued inhalers.
COMBIVENT Inhalation Aerosol is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
COMBIVENT Inhalation Aerosol was significantly more effective than ipratropium bromide or albuterol sulfate administered alone.
Adverse reactions, reported in less than two percent of the patients in the COMBIVENT Inhalation Aerosol treatment group include edema, fatigue, hypertension, dizziness, nervousness, paresthesia, tremor, dysphonia, insomnia, diarrhea, dry mouth, dyspepsia, vomiting, arrhythmia, palpitation, tachycardia, arthralgia, angina, increased sputum, taste perversion, and urinary tract infection/dysuria.
Allergic-type reactions such as skin rash, angioedema of tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been reported with Combivent.
Other common side effects may include headache, pain, influenza, nausea, rhinitis, sinusitis and coughing.
Use COMBIVENT Inhalation Aerosol exactly as prescribed by your doctor.
Do not change your dose or how often you use COMBIVENT Inhalation Aerosol without talking with your doctor.
NOTE: COMBIVENT Contains trichloromonofluoromethane (CFC-11), dichlorodifluoromethane (CFC-12) and dichlorotetrafluoroethane (CFC-114), substances which harm public health and the environment by destroying ozone in the upper atmosphere.
Since Combivent contains CFC it may not be available after December 2008.